Caplin Point Laboratories Limited (BOM: 524742)
India
· Delayed Price · Currency is INR | Market Cap | 175.67B |
| Revenue (ttm) | 18.33B |
| Net Income (ttm) | 4.94B |
| Shares Out | 76.01M |
| EPS (ttm) | 64.65 |
| PE Ratio | 35.75 |
| Forward PE | 32.06 |
| Dividend | 5.00 (0.22%) |
| Ex-Dividend Date | Sep 23, 2024 |
| Volume | 6,978 |
| Open | 2,380.85 |
| Previous Close | 2,393.60 |
| Day's Range | 2,311.00 - 2,410.00 |
| 52-Week Range | 1,221.00 - 2,540.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 7, 2024 |
About Caplin Point Laboratories
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic pharmaceutical formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry syrups, lyophilized vials, prefilled syringes, emulsion injection, and topicals. Caplin Point La... [Read more]
Financial Performance
In 2023, Caplin Point Laboratories's revenue was 16.96 billion, an increase of 15.51% compared to the previous year's 14.68 billion. Earnings were 4.57 billion, an increase of 21.48%.
Financial StatementsNews
Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion
Caplin Point Laboratories announced receiving final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05...
Caplin Point Laboratories shares hit new 52-week high this week; Check details
Caplin Point Laboratories shares made headlines this week by reaching a new 52-week high of ₹2,200.00 on November 29, 2024. The stock displayed impressive performance, supported by strong investor int...
Caplin Point Laboratories shares up 2% after strong Q2 performance
Caplin Point Laboratories has reported its financial results for the second quarter of FY25, showing impressive year-over-year (YoY) growth in both revenue from operations and net profit. Financial Hi...
Caplin Point Laboratories Q2 FY25 Results: Revenue rises 17.8% YoY to ₹483.10 crore, net profit up 12.7% YoY
Caplin Point Laboratories has announced its financial performance for the second quarter of FY25, showcasing notable growth in revenue from operations and net profit year-over-year (YoY). Financial Hi...
Top losers today: NMDC, Tata Steel, Finolex, Caplin Point, JSW Steel, and Jindal Steel lead declines
In early trade today, several stocks have posted significant losses, with metals and industrial sectors taking a hit. Here is a look at the top losers as of 9:44 AM: NMDC Ltd: ₹215.39 (-5.84%) Tata St...
Caplin Point Laboratories surges 6.77%, stock trading over ₹2025
Shares of Caplin Point Laboratories saw a significant rise, gaining 6.77% to trade at ₹2,026.40 as of 12:04 PM today. The stock opened at ₹1,900.00 and reached a high of ₹2,036.45, with a low of ₹1,89...
Caplin Point shares hit 52-week high, surge over 7%
As of 9:58 AM, the stock was trading at ₹2,107.55, marking a significant increase of ₹138.70 or 7.04% from its previous close. This surge propelled the stock to breach its previous 52-week high, setti...
Caplin Point shares surge 5% after Brazilian regulator clears Tamil Nadu facility
Caplin Point Laboratories’ shares saw a significant rise of over 5% after the Brazilian Health Regulatory Agency (ANVISA) gave a green light to the company’s manufacturing facility in Tamil Nadu. The ...